North America Cardiac Markers Market is expected to reach US$ 2.87 Billion by 2031

Analyzers Segment to Hold Significant North America Cardiac Markers Market Share During 2023–2031  

According to our latest study on "North America Cardiac Markers Market Forecast to 2031 – Regional Analysis – Product Type, Biomarker Type, Indication, End User, and Country," the market is expected to reach US$ 2.87 billion by 2031 from US$ 1.17 billion in 2023 and expected to register the CAGR of 11.8%. The report emphasizes the key factors driving the market and prominent players' developments. Factors such as the rising prevalence of cardiovascular diseases and a surge in the demand for point-of-care cardiac testing kits bolster the North America cardiac markers market. The report also includes growth prospects owing to the current North America cardiac markers market trends and their foreseeable impact during the forecast period.

Cardiac markers analyze specific proteins released into the bloodstream due to heart muscle damage or stress. Troponin, creatine kinase-MB (CK-MB), and myoglobin are indicators of cardiac damage that help diagnose a variety of cardiovascular diseases, including heart attacks, myocardial infarctions, and unstable angina. The severity of heart problems and treatment recommendations can be effectively determined with the use of cardiac markers. The adoption of cardiac markers has proven to improve patient outcomes and reduce mortality rates from cardiac events. Thus, the technological improvements in point-of-care testing have significantly impacted the cardiac marker market, owing to which it is widely used in emergency departments, intensive care units, and outpatient settings.

North America Cardiac Markers Market, by Region, 2023 (%)

Source: The Insight Partners Analysis

Rising Prevalence of Cardiovascular Diseases Drives North America Cardiac Markers Market Growth

Cardiovascular diseases (CVDs) include cerebrovascular disease, coronary artery disease (CAD), and rheumatic heart disease. Unhealthy diet, tobacco consumption, and physical inactivity are among the major lifestyle factors causing CVDs and related difficulties. The other risk factors related to CVDs are high blood pressure, diabetes, and elevated cholesterol levels. Heart attacks and strokes are mainly triggered by fatty deposits that block blood vessels, disrupting blood flow to the heart or brain. According to the National Center for Health Statistics, coronary heart disease accounts for nearly 25% of the total death count in the US each year. As per the Centers for Disease Control and Prevention (CDC), ~1.5 million cases of myocardial infarction are recorded annually in the US. A study published in Frontiers regarding Cardiovascular Medicine in September 2021 stated that myocardial infarction occurs every 40 seconds in the US, with a projected annual occurrence of 605,000 new cases and 200,000 recurring cases, and a prevalence of 3.0% in aging adults of 20 years and older. According to the Journal of Cardiac Failure, approximately 6.7 million Americans over the age of 20 experience heart failure, and the prevalence is expected to surge to 8.5 million by 2030.

According to the 2022 Heart Disease and Stroke Statistics Update Fact Sheet, in the US, approximately at every 40 seconds an individual is expected to have a myocardial infarction. Likewise, an updated report by the CDC in September 2021 states that ~6.5 million people aged 40 or more in the US have peripheral artery disease. The Heart and Stroke Foundation of Canada, in its February 2022 report, stated that 750,000 people suffer from heart failure, and 100,000 people are diagnosed with heart failure each year. Cardiac markers are used to diagnose and carry out the risk stratification among patients with chest pain and suspected acute coronary syndrome. These markers are also used for prognosis in patients with acute heart failure, pulmonary embolism, and other disease states. Thus, the demand for cardiac markers increases with the growing prevalence of CVDs, thereby fueling the North America cardiac markers market growth.

North America Cardiac Markers Market, by Product Type:

The North America cardiac markers market, based on product type, is segmented into reagents and kits, and analyzers. The analyzers segment held a larger market share in 2023. The reagents and kits segment is anticipated to register a higher CAGR of 12.4% during 2023–2031. Analyzers help track and analyze certain molecules or proteins in the blood that indicate heart disease or stress. A cardiac marker analyzer often uses immunoassay techniques to detect and measure the cardiac signals in a patient's blood sample. By analyzing and interpreting certain indicators related to heart problems, these analyzers significantly contribute to diagnosing the disease more accurately and quickly. These analyzers provide medical staff with important information about the patient's cardiac condition by analyzing certain markers such as myoglobin or troponins. Modern cardiac marker analyzers have improved turnaround time, sensitivity, and specificity.

North America Cardiac Markers Market, by Biomarker Type:

In terms of biomarker type, the North America cardiac markers market is segmented into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest market share in 2023 and is anticipated to register the highest CAGR during 2023–2031. The growth of the troponin segment can be due to the diagnostic efficiency, specificity, and accurate predictive detection of cardiac events. The industry's focus on introducing troponin tests with enhanced sensitivity to detect lower concentrations of troponin in blood samples is expected to drive the market for the segment. In July 2023, Mylab Discovery Solutions launched a diagnostic device powered by optical AI engines Mybox+ to provide accurate and rapid results in clinical samples for over 30 diseases. The device is ideal for small laboratories and centers and allows testing of cardiac markers (troponin) and biomarkers (CRP, D-dimer).

North America Cardiac Markers Market, by Indication:

By indication, the market is divided into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The congestive heart failure segment dominated the North America cardiac markers market share in 2023. The acute coronary syndrome segment is anticipated to register the highest CAGR of 12.5% during 2023–2031.

North America Cardiac Markers Market Analysis, by Region:

The regional scope of the North America cardiac markers market report covers three countries: the US, Canada, Mexico. The market growth in North America is attributed to the developed healthcare system and the high acceptance of cardiac markers for diagnosing and predicting diseases. In addition, the growing geriatric population needs biomarker testing for detecting conditions such as acute myocardial infarction, which, in turn, drives the expansion of the overall North America cardiac markers market size. The market in the US is expected to reach 2.39 billion by 2031 and is expected to register a CAGR of 11.9% during 2023–2031. The US holds the largest share of the North America cardiac markers market owing to increasing product development and growing government support for enhancing heart treatment. In addition, the growing prevalence of heart diseases and the risk involved have led to the market growth. According to the CDC, heart disease is one of the leading causes of death in the US. As per the same source, one person dies every 36 seconds because of CVD, i.e., approximately 655,000 Americans die from heart disease each year.

Apart from presenting the factors driving the market, the North America cardiac markers market report also emphasizes major developments by prominent players. Abbott Laboratories, F.Hoffmann-La Roche, Thermo Fischer Scientific Inc, Beckman Coulter  Inc, Bio-Rad Laboratories Inc, Creative Diagnostics, Diazyme Laboratories Inc, Biomerieux SA, Hytest Ltd, and QuidelOrtho Corp are among the prominent players operating in the market.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com